Not found

Aaron D. Thome, PhD

Assistant Research Professor of Neurology, Academic Institute
Assistant Research Member, Research Institute
Houston Methodist
Weill Cornell Medical College

Aaron D. Thome, Ph.D. grew up in Houston, Texas and completed his bachelor's degree in Biomedical Science at Texas A&M University in College Station, Texas. Following this, he completed his doctorate work at the Center for Neurodegeneration and Experimental Therapeutics (CNET) at the University of Alabama at Birmingham (UAB).  Dr. Thome's research here focused on microglial and neuroinflammatory mechanisms attributed to alpha-synuclein in models of Parkinson's disease. He then completed his Edwards Post-Doctoral Fellowship at the Houston Methodist Neurological Institute under Stanley H. Appel, M.D., the Edwards Distinguished Endowed Chair for ALS and Stanley H. Appel Department of Neurology Chair. Dr. Thome is currently primary faculty in the Houston Methodist Neurological Institute, Stanley H. Appel Department of Neurology, and Assistant Research Member for the Houston Methodist Research Institute.

Description of Research

Current research interest involves elucidating the underlying neuroinflammatory mechanisms in neurodegenerative disease, specifically in Parkinson's and Alzheimer's disease. His research utilizes human clinical samples and mouse pre-clinical models of disease to identify stage-specific immune changes in neurodegeneration and to develop translational therapeutics for immune modulation to target disease progression.

Areas Of Expertise

Neurodegenerative diseases Parkinson’s disease Microglia Neuroinflammation Immunomodulation Alzheimer's disease
Education & Training

Postdoctoral Fellowship, Houston Methodist Neurological Institute
PhD, University of Alabama at Birmingham (UAB)
BS, Texas A&M University

Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis
Beers, DR, Zhao, W, Neal, DW, Thonhoff, JR, Thome, AD, Faridar, A, Wen, S, Wang, J & Appel, SH 2020, , Scientific Reports, vol. 10, no. 1, 15295.

Immunosuppressive Functions of M2 Macrophages Derived from iPSCs of Patients with ALS and Healthy Controls
Zhao, W, Beers, DR, Thonhoff, JR, Thome, AD, Faridar, A, Wang, J, Wen, S, Ornelas, L, Sareen, D, Goodridge, HS, Svendsen, CN & Appel, SH 2020, , iScience, vol. 23, no. 6, 101192.

Functional alterations of myeloid cells during the course of Alzheimer's disease
Thome, AD, Faridar, A, Beers, DR, Thonhoff, JR, Zhao, W, Wen, S, Pascual, B, Masdeu, JC & Appel, SH 2018, Molecular Neurodegeneration, vol. 13, no. 1, pp. 61.

Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease
Williams, GP, Schonhoff, AM, Jurkuvenaite, A, Thome, AD, Standaert, DG & Harms, AS 2018, , Journal of Neuroinflammation, vol. 15, no. 1, 244.

Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease
Harms, AS, Thome, AD, Yan, Z, Schonhoff, AM, Williams, GP, Li, X, Liu, Y, Qin, H, Benveniste, EN & Standaert, DG 2018, , Experimental Neurology, vol. 300, pp. 179-187.

a-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration
Harms, AS, Delic, V, Thome, AD, Bryant, N, Liu, Z, Chandra, S, Jurkuvenaite, A & West, AB 2017, , Acta Neuropathologica Communications, vol. 5, no. 1.

The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia
Ponnazhagan, R, Harms, AS, Thome, AD, Jurkuvenaite, A, Gogliotti, R, Niswender, CM, Conn, PJ & Standaert, DG 2016, , Journal of Neuroimmune Pharmacology, vol. 11, no. 2, pp. 231-237.

MicroRNA-155 regulates alpha-synuclein-induced inflammatory responses in models of Parkinson disease
Thome, AD, Harms, AS, Volpicelli-Daley, LA & Standaert, DG 2016, , Journal of Neuroscience, vol. 36, no. 8, pp. 2383-2390.

Fractalkine signaling regulates the inflammatory response in an a-synuclein model of Parkinson disease
Thome, AD, Standaert, DG & Harms, AS 2015, , PLoS ONE, vol. 10, no. 10, e0140566.

MHCII is required for a-Synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration
Harm, AS, Cao, S, Rowse, AL, Thome, AD, Li, X, Mangieri, LR, Cron, RQ, Shacka, JJ, Raman, C & Standaert, DG 2013, , Journal of Neuroscience, vol. 33, no. 23, pp. 9592-9600.

A partial MECP2 duplication in a mildly affected adult male: A putative role for the 3' untranslated region in the MECP2 duplication phenotype
Hanchard, NA, Carvalho, CMB, Bader, P, Thome, A, Omo-Griffith, L, del Gaudio, D, Pehlivan, D, Fang, P, Schaaf, CP, Ramocki, MB, Lupski, JR & Cheung, SW 2012, , BMC Medical Genetics, vol. 13, 71.